drugset / Trial / NCT00005604
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Phase I trial to study the effectiveness of interleukin-12 plus interleukin-2 in treating patients who have advanced solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining the two drugs may kill more cancer cells
Timeline
- Start
- 2000-03
- Primary completion
- 2003-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | interleukin-12 | Protein / enzyme biologic | — | Intravenous |